Pharma & Biotech Events & Conferences
Refine Search
Biotechnology
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it released early-stage data on its FT819 in lupus. 19 November 2024
Pharmaceutical
US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). 18 November 2024
Pharmaceutical
French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from two Phase III open-label extension studies. 18 November 2024
Pharmaceutical
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE study of its Livdelzi (seladelpar). 16 November 2024
Pharmaceutical
French drugmaker Ipsen announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American Association for the Study of Liver Disease (AASLD) congress. 16 November 2024
Biotechnology
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. 13 November 2024
Biotechnology
Syndax Pharmaceuticals has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. 13 November 2024
Pharmaceutical
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data for its investigational medicine VK2738 at the ObesityWeek meeting. US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor domvanalimab in combination with zimberelimab. Denmark’s Novo Nordisk released financial results that attracted interest. 10 November 2024
Biotechnology
Shanghai-based BioCity Biopharma has announced promising late-stage results from the Phase II 2-SUCCEED clinical trial of SC0062. 7 November 2024
Biotechnology
Results from the ARC-10 Phase III study of Arcus Biosciences and Gilead Sciences’ domvanalimab and zimberelimab combination therapy indicate a significant reduction in mortality risk for patients with certain advanced lung cancers. 7 November 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased weight loss at higher doses. 4 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with mirikizumab sustained stable, long-term remission across two types of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease. 28 October 2024
Biotechnology
California’s Vera Therapeutics has released 96-week follow-up results from its ORIGIN Phase IIb trial of atacicept, targeting IgA nephropathy (IgAN). 28 October 2024
Pharmaceutical
US pharma major Bristol Myers Squibb has announced impressive results from the Phase III VALOR-HCM study, which showed the addition of mavacamten, an investigational, first-in-class cardiac myosin inhibitor, significantly reduced the need for septal reduction therapy (SRT) in patients with severely symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM) who had been appropriate for SRT. 4 April 2022
Pharmaceutical
US brain health specialist Sage Therapeutics has announced the presentation of data from the Phase II LUMINARY Study that showed SAGE-718, a first-in-class, oral, positive allosteric modulator of the NMDA receptor, was generally well-tolerated and associated with improvement on multiple tests of executive performance and learning and memory in patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). 2 April 2022
Biotechnology
Positive Phase II/III data for leniolisib have been presented at the annual congress of the Clinical Immunology Society (CIS 2022). 1 April 2022
Pharmaceutical
At AMCP 2022 in Chicago, new data from Janssen, the pharma arm of Johnson & Johnson (NYSE: JNJ), support the value of switching certain people with schizophrenia onto a long-acting treatment regimen. 31 March 2022
Biotechnology
German family-owned pharma major Boehringer Ingelheim today announced new data from the pivotal Phase II Effisayil 1 trial, presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston. 28 March 2022
Biotechnology
At this year’s annual congress of the American Academy of Dermatology (AAD), Incyte has announced new one-year results for Opzelura (ruxolitinib cream). 28 March 2022
Biotechnology
French drugmaker Sanofi and partner Regeneron have announced positive results from the Phase III PRIME2 trial of Dupixent (dupilumab) at the American Academy of Dermatology (AAD) 2022 Annual Meeting. 28 March 2022
Biotechnology
Adults with severe alopecia areata (AA) who took Olumiant (baricitinib) achieved significant scalp, eyelash and eyebrow hair regrowth and nearly 75% of those who responded to Olumiant 4mg achieved 90% scalp coverage at 52 weeks, Eli Lilly and Incyte announced at the American Academy of Dermatology (AAD) Annual Meeting on March 26. 28 March 2022
Pharmaceutical
Shares of Timber Pharmaceuticals rose as much as 14% to $0.41 yesterday, after the rare and orphan dermatologic diseases announced a late-breaking presentation of a sub-analysis of the Phase IIb CONTROL study that evaluated TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, at the American Academy of Dermatology (AAD) 2022 Annual Meeting being held in Boston, MA, from March 25-29 26 March 2022
Pharmaceutical
Dermavant Sciences, an immuno-dermatology-focused subsidiary of Switzerland-based Roivant Sciences, has announced Phase III PSOARING 3 long-term extension study results demonstrating durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily (QD) for the treatment of plaque psoriasis in adults. 25 March 2022
Biotechnology
Japan’s Eisai and Biogen today announced that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually. 22 March 2022
Pharmaceutical
At the annual congress of the Muscular Dystrophy Association (MDA), Swiss pharma giant Roche has announced new data for its spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). 16 March 2022
Biotechnology
US biotech major Biogen today announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RESPOND and NURTURE studies. 14 March 2022
Pharmaceutical
Avadel Pharmaceuticals is presenting new data in eight posters at the World Sleep 2022 congress in Rome. 14 March 2022
Biosimilars
South Korea’s Celltrion Healthcare announced new data sets on the SC formulation of infliximab, Remsima (CT-P13) in IBD, at the European Crohn’s and Colitis Organization (ECCO) virtual congress 2022. 21 February 2022
Biotechnology
More positive data for the leading PARP blocker, Lynparza (olaparib), are being presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. 15 February 2022
Biotechnology
Cumulative five-year results from two Phase III studies (Study 1489 and Study 1490) of Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) were announced on Friday. 12 February 2022
Biotechnology
US pharma giant Merck & Co has announced the final results from the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab) plus best supportive care (BSC) in patients in Asia with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib. 19 January 2022
Biotechnology
Positive results from the HIMALAYA Phase III trial showed a single priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically-significant and clinically-meaningful improvement in overall survival (OS) versus sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment. 19 January 2022
Biotechnology
The UK life science sector is playing a leading role at this year’s JP Morgan healthcare conference, being held virtually, the traditional kick off annual event for the global life science investment community. 11 January 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze